메뉴 건너뛰기




Volumn 57, Issue 6, 2016, Pages 867-871

Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients

Author keywords

68Ga gallium; Affibody; Breast cancer metastases; Dosimetry; HER2 receptor

Indexed keywords

GALLIUM ABY 025 GA 68; RADIOISOTOPE; UNCLASSIFIED DRUG; ABY-025; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GALLIUM; PEPTIDE FRAGMENT; STAPHYLOCOCCUS PROTEIN A;

EID: 84973595060     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.169342     Document Type: Article
Times cited : (98)

References (25)
  • 1
    • 84862894846 scopus 로고    scopus 로고
    • Pertuzumab monotherapy after trastuzumabbased treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
    • Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumabbased treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:1594-1600.
    • (2012) J Clin Oncol , vol.30 , pp. 1594-1600
    • Cortés, J.1    Fumoleau, P.2    Bianchi, G.V.3
  • 2
    • 80052593511 scopus 로고    scopus 로고
    • HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis
    • Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat. 2011;129:659-674.
    • (2011) Breast Cancer Res Treat , vol.129 , pp. 659-674
    • Houssami, N.1    Macaskill, P.2    Balleine, R.L.3    Bilous, M.4    Pegram, M.D.5
  • 3
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 4
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 5
    • 84891781085 scopus 로고    scopus 로고
    • A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
    • Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277-289.
    • (2014) Eur J Cancer , vol.50 , pp. 277-289
    • Aurilio, G.1    Disalvatore, D.2    Pruneri, G.3
  • 6
    • 78650986693 scopus 로고    scopus 로고
    • HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression
    • Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125:553-561.
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 553-561
    • Wilking, U.1    Karlsson, E.2    Skoog, L.3
  • 7
    • 84893691711 scopus 로고    scopus 로고
    • Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
    • Karlsson E, Sandelin K, Appelgren J, et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Eur J Cancer. 2014;50:517-524.
    • (2014) Eur J Cancer , vol.50 , pp. 517-524
    • Karlsson, E.1    Sandelin, K.2    Appelgren, J.3
  • 8
    • 84864085607 scopus 로고    scopus 로고
    • Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression
    • Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-2608.
    • (2012) J Clin Oncol , vol.30 , pp. 2601-2608
    • Lindström, L.S.1    Karlsson, E.2    Wilking, U.M.3
  • 9
    • 84906053842 scopus 로고    scopus 로고
    • 111 In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment
    • Gaykema SB, de Jong JR, Perik PJ, et al. 111In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014;13.
    • (2014) Mol Imaging , vol.13
    • Gaykema, S.B.1    De Jong, J.R.2    Perik, P.J.3
  • 10
    • 77951474500 scopus 로고    scopus 로고
    • 89 Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer
    • Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 586-592
    • Dijkers, E.C.1    Oude Munnink, T.H.2    Kosterink, J.G.3
  • 11
    • 77954963897 scopus 로고    scopus 로고
    • 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold
    • Ahlgren S, Orlova A, Wallberg H, et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010;51:1131-1138.
    • (2010) J Nucl Med , vol.51 , pp. 1131-1138
    • Ahlgren, S.1    Orlova, A.2    Wallberg, H.3
  • 13
    • 77951768789 scopus 로고    scopus 로고
    • Design of an optimized scaffold for affibody molecules
    • Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol. 2010;398:232-247.
    • (2010) J Mol Biol , vol.398 , pp. 232-247
    • Feldwisch, J.1    Tolmachev, V.2    Lendel, C.3
  • 14
    • 84901325574 scopus 로고    scopus 로고
    • 111In-ABY-025 affibody molecule
    • Sörensen J, Sandberg D, Sandstrom M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55:730-735.
    • (2014) J Nucl Med , vol.55 , pp. 730-735
    • Sörensen, J.1    Sandberg, D.2    Sandstrom, M.3
  • 15
    • 79953766951 scopus 로고    scopus 로고
    • Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
    • Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38:531-539.
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 531-539
    • Tolmachev, V.1    Wallberg, H.2    Sandstrom, M.3    Hansson, M.4    Wennborg, A.5    Orlova, A.6
  • 16
    • 84861861669 scopus 로고    scopus 로고
    • Tumor targeting using Affibody molecules: Interplay of affinity, target expression level, and binding site composition
    • Tolmachev V, Tran TA, Rosik D, Sjoberg A, Abrahmsen L, Orlova A. Tumor targeting using Affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012;53: 953-960.
    • (2012) J Nucl Med , vol.53 , pp. 953-960
    • Tolmachev, V.1    Tran, T.A.2    Rosik, D.3    Sjoberg, A.4    Abrahmsen, L.5    Orlova, A.6
  • 17
    • 84954520777 scopus 로고    scopus 로고
    • 68Ga]ABY-025 Affibody PET/CT
    • Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016;6:262-271.
    • (2016) Theranostics , vol.6 , pp. 262-271
    • Sörensen, J.1    Velikyan, I.2    Sandberg, D.3
  • 18
    • 84938362385 scopus 로고    scopus 로고
    • GMP compliant preparation of a 68gallium-labeled Affibody analogue for breast cancer patient examination: Firstin-man
    • Velikyan I, Wennborg A, Feldwisch J, et al. GMP compliant preparation of a 68gallium-labeled Affibody analogue for breast cancer patient examination: firstin-man. Eur J Nucl Med Mol Imaging. 2014;41(suppl):S228-S229.
    • (2014) Eur J Nucl Med Mol Imaging , vol.41 , pp. S228-S229
    • Velikyan, I.1    Wennborg, A.2    Feldwisch, J.3
  • 19
    • 2442649352 scopus 로고    scopus 로고
    • 68 Ga bioconjugates with high specific radioactivity
    • Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-560.
    • (2004) Bioconjug Chem , vol.15 , pp. 554-560
    • Velikyan, I.1    Beyer, G.J.2    Langstrom, B.3
  • 20
    • 67349222944 scopus 로고    scopus 로고
    • 177Lu-DOTA0,Tyr3]octreotate
    • Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-1146.
    • (2009) Eur J Nucl Med Mol Imaging , vol.36 , pp. 1138-1146
    • Forrer, F.1    Krenning, E.P.2    Kooij, P.P.3
  • 21
    • 0030002992 scopus 로고    scopus 로고
    • MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
    • Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
    • (1996) J Nucl Med , vol.37 , pp. 538-546
    • Stabin, M.G.1
  • 23
    • 23044470017 scopus 로고    scopus 로고
    • OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine
    • Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
    • (2005) J Nucl Med , vol.46 , pp. 1023-1027
    • Stabin, M.G.1    Sparks, R.B.2    Crowe, E.3
  • 24
    • 84859648576 scopus 로고    scopus 로고
    • 89Zr-ibritumomab tiuxetan and PET
    • Rizvi SN, Visser OJ, Vosjan MJ, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39:512-520.
    • (2012) Eur J Nucl Med Mol Imaging , vol.39 , pp. 512-520
    • Rizvi, S.N.1    Visser, O.J.2    Vosjan, M.J.3
  • 25
    • 1542438683 scopus 로고    scopus 로고
    • Chapter I: Food and Drug Administration Department of Health and Human Services. Subchapter D: Drugs for Human Use. Part 361: Prescription Drugs for Human Use Generally Recognized as Safe and Effective and Not Misbranded - Drugs Used in Research. Accessed February 25, 2016
    • Title 21: Food and drugs. Chapter I: Food and Drug Administration Department of Health and Human Services. Subchapter D: Drugs for Human Use. Part 361: Prescription Drugs for Human Use Generally Recognized as Safe and Effective and Not Misbranded - Drugs Used in Research. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart5361&showFR51. Accessed February 25, 2016.
    • Food and Drugs
    • Title 211


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.